LOGIN  |  REGISTER

Asensus Surgical to Participate in the H.C. Wainwright 25th Annual Global Investment Conference and 2023 Cantor Global Healthcare Conference

September 05, 2023 | Last Trade: US$0.35 0.00 0.00

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference. The Company’s fireside chat will take place on Monday, September 11, 2023 at 3:00 pm Eastern Time.

In addition, the Company will participate in the 2023 Cantor Global Healthcare Conference. The Company’s fireside chat will take place on Tuesday, September 26, 2023 at 4:20 pm Eastern Time.

Each of the conference webcasts will be available online on the investor relations page of the Company’s website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website for approximately 90 days.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance® Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com

Follow Asensus:

Email Alerts: https://ir.asensus.com/email-alerts 
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc 
Twitter: https://twitter.com/AsensusSurgical 
YouTube: https://www.youtube.com/@AsensusSurgical 
Vimeo: https://vimeo.com/asxc 
TikTok: https://www.tiktok.com/@asensus_surgical 

INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it. 
443-213-0499

MEDIA CONTACT:
Dan Ventresca
Matter Communications
This email address is being protected from spambots. You need JavaScript enabled to view it. 
617-874-5488

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB